NRSN
NeuroSense Therapeutics Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+44/100
Last price
4.07
▲ 0.04 (0.99%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
4.03
Day high
4.28
Day low
3.94
Volume
17.78K
Market cap
$7.72M
P/E (TTM)
—
52W range
3.82 – 26.64
Trailing performance
Returnvs SPY
1W
-14.85%
-16.8%
1M
+696.48%
+695.3%
3M
+474.05%
+469.5%
6M
+435.53%
+417.3%
YTD
+429.26%
+415.0%
1Y
+225.60%
+209.2%
3Y
+473.24%
+391.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NRSN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
555.33K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 16, 26 | EISENBERG OR Chief Financial Officer |
BUY | 250.00K | $200.00K | Direct |
| Jun 16, 26 | BEN-NOON ALON Chief Executive Officer |
BUY | 250.00K | $200.00K | Direct |
| Mar 26, 26 | EISENBERG OR Chief Financial Officer |
— | 200.00K | — | Direct |
| Mar 26, 26 | BINDER HAGIT Officer |
— | 200.00K | — | Direct |
| Mar 26, 26 | RUSSEK-BLUM NIVA Chief Technology Officer |
— | 200.00K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEN-NOON ALON |
Chief Executive Officer | 4.53M | Purchase |
BINDER HAGIT |
Officer | 521.81K | Stock Award(Grant) |
EISENBERG OR |
Chief Financial Officer | 1.50M | Purchase |
RUSSEK-BLUM NIVA |
Chief Technology Officer | 467.95K | Stock Award(Grant) |
Fundamentals
Market cap$7.72M
Enterprise value$7.20M
Revenue (TTM)—
Gross profit—
EBITDA$-11.07M
Net income$-11.13M
EPS (TTM)$-47.10
Free cash flow$-3.87M
Total cash$166.00K
Total debt$170.00K
Book value / share$-0.96
Shares outstanding1.90M
Float1.19M
Short % of float2.56%
Dividend yield0.00%
Beta (5Y)1.64
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.35
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA-0.65
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-2174.98%
Return on assets-247.30%
Debt / equity—
Current ratio0.31
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $6.23M | $5.70M | $7.27M | $5.59M | +9.3% |
| Selling, general & admin | $4.86M | $4.20M | $4.78M | $4.97M | +15.6% |
| Total operating expense | $11.09M | $9.90M | $12.05M | $10.55M | +11.9% |
| Operating income | -$11.09M | -$9.90M | -$12.05M | -$10.55M | -11.9% |
| Net interest income | $7.00K | -$309.00K | -$270.00K | $84.00K | +102.3% |
| Pre-tax income | -$11.13M | -$10.21M | -$10.11M | -$10.49M | -9.0% |
| Net income | -$11.13M | -$10.21M | -$10.11M | -$10.49M | -9.0% |
| Net income to common | -$11.13M | -$10.21M | -$10.11M | -$10.49M | -9.0% |
| Basic EPS | -0.44 | -0.54 | -0.74 | -0.91 | +18.5% |
| Diluted EPS | -0.44 | -0.54 | -0.74 | -0.91 | +18.5% |
| EBIT | -$11.09M | -$9.90M | -$12.05M | -$10.55M | -11.9% |
| EBITDA | -$11.07M | -$9.88M | -$12.03M | -$10.54M | -12.0% |
| Basic shares | 25.48M | 18.91M | 13.64M | 11.50M | +34.8% |
| Diluted shares | 25.48M | 18.91M | 13.64M | 11.50M | +34.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $166.00K | $3.38M | $2.64M | $3.54M | -95.1% |
| Cash & short-term investments | $166.00K | $3.38M | $2.64M | $7.09M | -95.1% |
| Total current assets | $778.00K | $4.40M | $2.92M | $7.38M | -82.3% |
| Property, plant & equipment | $228.00K | $150.00K | $247.00K | $306.00K | +52.0% |
| Total assets | $1.03M | $4.58M | $3.19M | $7.71M | -77.5% |
| Total current liabilities | $2.52M | $1.99M | $3.46M | $1.73M | +26.3% |
| Total debt | $170.00K | $73.00K | $142.00K | $211.00K | +132.9% |
| Total liabilities | $2.59M | $1.99M | $4.94M | $2.09M | +29.9% |
| Retained earnings | -$47.78M | -$36.66M | -$26.12M | -$20.79M | -30.3% |
| Shareholder equity | -$1.56M | $2.58M | -$1.76M | $5.62M | -160.4% |
| Working capital | -$1.74M | $2.41M | -$543.00K | $5.66M | -172.1% |
| Net tangible assets | -$1.56M | $2.58M | -$1.76M | $5.62M | -160.4% |
| Shares issued | 32.56M | 23.23M | 15.38M | 11.78M | +40.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$11.13M | -$10.21M | -$10.11M | -$10.49M | -9.0% |
| Depreciation & amortisation | $16.00K | $22.00K | $21.00K | $12.00K | -27.3% |
| Stock-based compensation | $2.14M | $557.00K | $1.54M | $1.73M | +284.2% |
| Change in working capital | $1.34M | -$781.00K | $1.91M | $1.09M | +272.1% |
| Operating cash flow | -$7.67M | -$10.13M | -$8.35M | -$7.62M | +24.3% |
| Capital expenditure | -$8.00K | -$3.00K | -$29.00K | -$70.00K | -166.7% |
| Investing cash flow | -$8.00K | $1.00K | $3.47M | -$3.59M | -900.0% |
| Financing cash flow | $4.43M | $10.91M | $3.98M | $3.77M | -59.4% |
| Free cash flow | -$7.68M | -$10.14M | -$8.38M | -$7.69M | +24.3% |
| End cash position | $166.00K | $3.38M | $2.64M | $3.54M | -95.1% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $166.00K | $666.00K | -75.1% |
| Cash & short-term investments | $166.00K | $666.00K | -75.1% |
| Total current assets | $778.00K | $1.56M | -50.0% |
| Property, plant & equipment | $228.00K | $105.00K | +117.1% |
| Total assets | $1.03M | $1.68M | -39.0% |
| Total current liabilities | $2.52M | $2.20M | +14.2% |
| Total debt | $170.00K | — | — |
| Total liabilities | $2.59M | $2.20M | +17.5% |
| Retained earnings | -$47.78M | -$41.37M | -15.5% |
| Shareholder equity | -$1.56M | -$519.00K | -200.6% |
| Working capital | -$1.74M | -$647.00K | -168.6% |
| Net tangible assets | -$1.56M | -$519.00K | -200.6% |
| Shares issued | 32.56M | 24.60M | +32.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2025 | -0.80 | — | — |
| Sep 2025 | -0.80 | — | — |
| Jun 2025 | -7.40 | — | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -3.40 | 1 | $0 | 0.0% |
| Next quarter | — | — | $0 | — |
| Current year | -6.23 | 2 | $0 | 0.0% |
| Next year | -11.76 | 2 | $2.70M | 0.0% |
Analyst targets & ownership
Mean target$97.33
High target$180.00
Low target$52.00
Implied upside2291.48%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy0 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders31.42%
Held by institutions1.05%
Institutions holding13
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.21
-21.95% from price
SMA 20
5.03
-19.02% from price
SMA 50
3.03
+34.41% from price
SMA 100
1.89
+115.68% from price
SMA 200
1.37
+197.27% from price
EMA 12
4.71
-13.55% from price
EMA 26
4.18
-2.71% from price
EMA 50
3.30
+23.30% from price
RSI (14)
49.6
Neutral
MACD (12,26,9)
0.52
Hist -0.39
ATR (14)
0.74
18.15% of price
Realised vol 30D
871.4%
Annualised
Bollinger upper
9.64
20, 2σ
Bollinger lower
0.42
20, 2σ
50 / 200 cross
Golden
3.03 vs 1.37
Trend bias
Above 200
+197.27%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.98
More volatile than market
Correlation to SPY
0.01
Largely independent
Realised vol 30D
871.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-96.8%
Peak to trough
Max drawdown 5Y
-96.8%
Peak to trough
ATR 14
0.74
18.15% of price
Beta (reported)
1.64
5Y monthly, from filing
Short interest
Shares short
38.24K
Prior 24.46K
Change vs prior
+56.3%
Shorts adding
% of float
2.56%
Normal
% of shares out
2.02%
Against total outstanding
Days to cover
1.3
Liquid
Float
1.19M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 3, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Apr 8, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 25, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 17, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 10, 26 | Roth Capital | INITIATED | — | Buy |
| Mar 9, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Dec 22, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Nov 24, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Aug 15, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jul 10, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| May 12, 25 | D. Boral Capital | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:20
Split dateSep 14, 2026
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-02
Corporate Changes & Voting Matters
6-K · 2026-09-25
Corporate Changes & Voting Matters
6-K · 2026-09-09
Corporate Changes & Voting Matters
6-K · 2026-08-27
Corporate Changes & Voting Matters
6-K · 2026-08-13
Corporate Changes & Voting Matters
6-K · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-07-31
Offering Registrations
F-3/A · 2026-07-30
Headlines
Neurosense Therapeutics Receives Nasdaq Listing Compliance Notice
MT Newswires · 5d ago
NeuroSense Provides Update on Nasdaq Listing Compliance
PR Newswire · 5d ago
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
PR Newswire · 9d ago
NeuroSense Provides Business Update and Progress for the First Half of 2026
PR Newswire · 12d ago
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire · 27d ago
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
PR Newswire · 37d ago
NeuroSense Issues CEO Letter to Shareholders
PR Newswire · 55d ago
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
PR Newswire · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.